x

Posted 08 December, 2021

PPD, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:PPD in a 8-K filed on 08 December, 2021.


  In addition, effective upon the consummation of the Merger, David Simmons, the Company's Chief Executive Officer, Christopher Scully, the Company's Executive Vice President and Chief Financial Officer, William Sharbaugh, the Company's Chief Operating Officer, Anshul Thakral, the Company's Chief Commercial Officer and Executive Vice President, Peri- and Post-Approval Services, and Glen Donovan, the Company's Chief Accounting Officer, ceased serving as officers of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of PPD, Inc.
None • None
Pharmaceutical Product Development LLC is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Its services include contact services, discovery, early development, clinical development, laboratories, post-approval, PPD consulting and industry expertise. The firm operates in the therapeutic areas that include cardiovascular, critical care, dermatology, dental pain research, endocrine and metabolics, gastroenterology, hematology and oncology, immunology, infectious diseases, neuroscience, ophthalmology, respiratory and urology. The company was founded in 1985 by Fredric N. Eshelman and is headquartered in Wilmington, NC.
Market Cap
N/A
View Company Details
PPD, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


In connection with the consummation of the Merger, at the Effective Time, all of the directors of the Company ceased to serve as the directors of the Surviving Corporation.

At the Effective Time, in connection with the Merger and in accordance with the terms of the Merger Agreement, Michael Boxer, Anthony Hugh Smith and Maura A. Spellman, who served as the directors of Merger Sub immediately prior to the Effective Time, listed below, became the directors of the Surviving Company. 

Also in connection with the consummation of the Merger, immediately following the Effective Time, David Johnston was appointed as President of the Company. David Johnston, Ph.D., served as the Company's Executive Vice President of Global Clinical Development from October 2016 until this appointment. From July 2013 to September 2016, Dr. Johnston served as Executive Vice President and Global Head of PPD Laboratories. Prior to joining the Company, Dr. Johnston worked at Laboratory Corp of America (LH) from April 1998 to June 2013, where he most recently served as Senior Vice President and Global Head of the Clinical Trials business. 

In addition, effective upon the consummation of the Merger, David Simmons, the Company's Chief Executive Officer, Christopher Scully, the Company's Executive Vice President and Chief Financial Officer, William Sharbaugh, the Company's Chief Operating Officer, Anshul Thakral, the Company's Chief Commercial Officer and Executive Vice President, Peri- and Post-Approval Services, and Glen Donovan, the Company's Chief Accounting Officer, ceased serving as officers of the Company. Messrs. Thakral and Donovan remain employed by the Company in a non-officer capacity.